Abstract-In serum, human paraoxonase/arylesterase (PON1) is found exclusively associated with high density lipoprotein (HDL) and contributes to its antiatherogenic properties by inhibiting low density lipoprotein (LDL) oxidation. Difficulties in purifying PON1 from apolipoprotein A-I (apoA-I) suggested that PON1's association with HDL may occur through a direct binding between these 2 proteins. An unusual property of PON1 is that the mature protein retains its hydrophobic N-terminal signal sequence. By expressing in vitro a mutant PON1 with a cleavable N-terminus, we demonstrate that PON1 associates with lipoproteins through its N-terminus by binding phospholipids directly rather than binding apoA-I. Nonetheless, apoA-I stabilized arylesterase activity more than did phospholipid alone, apoA-II, or apoE. Consequently, we studied the role of apoA-I in PON1 expression and HDL association in mice genetically deficient in apoA-I. Though present in HDL fractions at decreased levels, PON1 arylesterase activity was less stable than in control mice. Furthermore, PON1 could be competitively removed from HDL by phospholipids, suggesting that PON1's retained N-terminal peptide allows transfer of the enzyme between phospholipid surfaces. Thus, our data suggest that PON1 is stabilized by apoA-I, and its binding to HDL and physiological distribution are dependent on the direct binding of the retained hydrophobic N-terminus to phospholipids optimally presented in association with apoA-I. (Arterioscler Thromb Vasc Biol. 1999;19
H uman serum paraoxonase/arylesterase (PON1) is exclusively associated with HDLs and is a genetically polymorphic enzyme that has the ability to hydrolyze a wide range of organophosphates and carboxyesters. 1 In addition, PON1 is 1 of the few enzymes or modifying transfer proteins that interacts with serum lipoproteins. Nevertheless, surprisingly little is known about the requirements for PON1 to associate with HDL or the structure of its endogenous substrates. Epidemiological and biochemical evidence is accumulating, however, which indicates that PON1 catalyzes the removal of the biologically active products of lipid peroxidation [2] [3] [4] [5] [6] and that the aforementioned genetic polymorphism may result in phenotypes with different susceptibilities to coronary heart disease. [7] [8] [9] [10] [11] [12] [13] [14] [15] In humans, a wellestablished inverse relationship exists between plasma HDL levels and cardiovascular disease. 16, 17 The antiatherogenic qualities of HDL may in part be due to the activities of PON1. Indeed, PON1-deficient mice are more susceptible to organophosphate toxicity as well as to diet-induced atherosclerosis than are their wild-type littermates. 18 The exclusive association of circulating PON1 with HDL also implies that PON1's expression and biological role are affected by other HDL-associated proteins. For example, PON1 may only encounter its endogenous substrates and have biological significance in vivo if the enzyme is distributed with HDL. Therefore, the structural features of PON1 that determine its association with HDL may be as important as its catalytic components. Other apolipoproteins may contribute to PONЈs association with HDL. In this regard, immunopurified PON1 is found to be associated with 2 major proteins, apoA-I and apoJ. 19, 20 Furthermore, Blatter and coworkers 20 demonstrated that 90% of PON1 coimmunopurifies with anti-apoA-I antibodies, 30% coimmunopurifies with anti-apoJ antibodies, and 10% coimmunopurifies with anti-apoA-II antibodies. In all cases, apoA-I coimmunopurified with PON1, regardless of which antibodies were used. Thus, these studies suggest that virtually all PON1 is associated with apoA-I. It is notable, however, that PON1 does not coimmunopurify with any apolipoproteins in the presence of nonionic detergents. 21 These findings are consistent with the fact that separating the enzyme from apoA-I was a significant advance in the purification of PON1. Interestingly, the isolation of PON1 in an active form was found to be possible only through the addition of a nonionic detergent. 22, 23 The close association between PON1 and apoA-I suggests direct binding of the 2 proteins. Direct sequencing of PON1 purified from human and rabbit sera has demonstrated an unusual property: in both species, the mature, circulating form retains its N-terminal hydrophobic signal sequence. 20,24 -26 This observation has led to the suggestion that PON1's hydrophobic N-terminal sequence may facilitate its association with HDL. Retention of this signal peptide has been postulated to be the consequence of an evolutionary substitution of large, polar residues at the signal-peptide cleavage site where smaller residues are typically present, thereby eluding cleavage by signal peptidases. 25, 26 The presence of similar large, polar residues in the deduced N-terminal sequence from mouse PON1 suggests that it is also retained ( Figure 1 ) and that this is a generalized feature of mammalian PON1s. [27] [28] [29] We postulated that changing the histidine (H) and glutamine (Q) residues in positions 20 and 21, respectively, to alanines by mutagenesis would allow the in vitro expression of a normally processed and secreted PON1 enzyme. The expressed protein would have its N-terminal hydrophobic signal sequence cleaved and serve as a model to determine whether this region is required for PON1's association with lipoproteins. In the current study, we present evidence that the retained N-terminal hydrophobic signal peptide is the structural requirement for PON1 to associate with HDL. We also show that the N-terminal peptide binds to phospholipids directly, in the absence of any apolipoproteins. Furthermore, using apoA-I-deficient mice, we define a role for this protein in stabilizing PON1. The association of PON1 and apoA-I with HDL appears to be largely mediated through their common binding to lipids rather than a direct binding between them. Hence, PON1 is able to circulate with HDL by directly binding to HDLassociated phospholipids through its retained N-terminal hydrophobic peptide.
Methods

Site-Directed Mutagenesis
Creation of wild-type PON1 (type Q) and its sequence verification have been described previously. 27 To allow the recombinant, mutant PON1 enzyme to be normally targeted to the endoplasmic reticulum for appropriate folding, glycosylation, and signal-sequence cleavage, we chose to mutate both residues H20 and Q21 to create a theoretically cleavable site. These specific residues were chosen because they were in the Ϫ3 position from the predicted cleavage site if small, nonpolar residues were in their place. 26, 30, 31 Sitedirected mutagenesis to replace H20 and Q21 simultaneously with alanines was accomplished as described previously by using wildtype PON1 (type Q) as a template with a mutagenic polymerase chain reaction primer to create the cDNA for PON1 (type Q) A20A21 (5Ј-CTGGCACTCTTCAGGAACGCCGCGTCTTCTTA-CCAAACACGA-3Ј). The nucleotide sequence of the entire coding region of PON1 (type Q) A20A21 was determined by the University of Michigan DNA Sequencing Core Facility by automated fluorescent sequencing and manually using dideoxy chemistry (fmol Cycle Sequencing Kit from Promega). The mutant cDNA was subcloned into a pGS expression vector as previously described. 27 
Transfection
Human embryonic kidney 293T/17 cells were grown in 10% FBS in minimal essential medium with Earle's salts (MEM) at 37°C, 95% humidity, and 5% CO 2 . Transfection was performed with calcium phosphate precipitates as described elsewhere 32 by using 20 g of plasmid DNA. Recombinant enzyme was collected in MEM with either 1% or 10% FBS 96 hours after removal of the DNA. Control medium was obtained by transfecting, washing, and collecting medium as described above, except that the pGS vector without the cDNA insert was used. In all cases, the control and experimental media being compared were collected from an equal number of simultaneously transfected cells, in the identical preparation of culture medium, and the same duration of collection of expressed enzyme. Expression medium was concentrated 10-fold with a Centriprep 30 (Amicon) according to the manufacturer's instructions.
Preparation of Cell Extracts
Adherent cells were trypsinized after collection of media, suspended in PBS, and pelleted by centrifugation at 1000g for 10 minutes. The supernatant was removed and the cells were washed by resuspension in PBS. The procedure was repeated 2 times, and the pelleted cells were resuspended in 1 mL of 50 mmol/L Tris-Cl, pH 8.0, containing 1 mmol/L CaCl 2 and 1% Triton X-100 (Sigma Chemical Co). The suspension was then centrifuged at 12 000g and the supernatant was removed for further use.
Activity Assays/Kinetics
Arylesterase activities were determined by using phenyl acetate as a substrate according to Eckerson et al. 33 In brief, unless otherwise specified, all activities were measured at 270 nm in a dual-beam spectrophotometer at 25°C in 50 mmol/L Tris-Cl, pH 8.0, and 1 mmol/L CaCl 2 , with the reference cuvette being identical to the experimental one except for the addition of expression medium to the experimental cuvette. Except for determining kinetic constants, all assays were performed with 1 mmol/L phenyl acetate as a substrate. Background activities were determined for all substrates at all concentrations by measuring the activity in the control medium. This background activity was subtracted to give the net activity of the expressed enzymes. Apparent Michaelis constants (K m ) and maximal velocities (V max ) were derived from Eadie-Hoffstee plots through least-squares regression with the use of Statview software (SAS Institute Inc).
Preparation of Lipid Vesicles and Proteoliposomes
Vesicles without apolipoprotein (PC/C vesicles) and proteoliposome vesicles containing human apoA-I (AI/PC/C vesicles), human apoA-II (AII/PC/C vesicles), or human apoE (E/PC/C vesicles) were prepared by the cholate dialysis method essentially as described by Chen and Albers. 34 Purified, lyophilized preparations of apo A-I, A-II, and E isolated from pooled, human plasma were a gift from Dr Conrad Blum (Columbia University College of Physicians and Surgeons, New York, NY). 35, 36 PC/C vesicles were prepared with egg phosphatidylcholine/cholesterol in a molar ratio of 250:12.5 in the presence of sodium cholate, whereas proteoliposomes were prepared containing apolipoprotein/egg phosphatidylcholine/cholesterol in a molar ratio of 0.8:250:12.5, also in the presence of sodium Figure 1 . Large, polar residues inhibit cleavage of the PON1 N-terminal hydrophobic signal peptide. Numbering begins with the initiation methionine as 1 even though it is not present in the mature protein. Dashes indicate identity with the human sequence. Italicized, boldface letters indicate residues constituting the hydrophobic core of the leader sequence. Nonitalicized, enlarged, boldface letters indicate amino acid residues in the postulated Ϫ3 positions from the theoretical cleavage sites. These residues were both changed to alanines in the A20A21 N-terminal mutant. Asterisks indicate theoretical cleavage sites.
cholate as described. 34 Two separate vesicle batches containing different concentrations of Tris-Cl and CaCl 2 were made. Cholate was removed from the vesicles by extensive washing in Centriflo CF25 ultrafiltration membrane cones (Amicon). For the first batch, PC/C and AI/PC/C vesicles were prepared with 10 mmol/L TrisHCl, pH 8.0, containing 0.2 mmol/L CaCl 2 as both the vesicle preparation and dialysis buffer. For the second batch, we prepared PC/C, AI/PC/C, AII/PC/C (molar ratio based on the monomeric form of apoA-II), or E/PC/C vesicles; however, 50 mmol/L Tris-HCl, pH 8.0, containing 1.0 mmol/L CaCl 2 was used for the dialysis step. After dialysis, preparations were adjusted with dialysis buffer to 36 mol/L apoA-I (batch 1) or to 30 mol/L apolipoproteins (batch 2). Vesicles without apolipoproteins were adjusted to an equal volume of dialysis buffer, and all preparations were stored at 4°C until use. The apolipoprotein preparations alone or when reconstituted as vesicles had no detectable arylesterase activity.
Purification of Human PON1
Human serum PON1 (type Q) was purified as described by Gan et al 23 and later modified by Kuo and La Du. 22 Incubations/Size-Exclusion Chromatography Media (500 L, containing 1.9 mmol/L CaCl 2 ) from control (pGS vector without cDNA insert), A20A21 mutant, and wild-type (type Q) PON1s were individually incubated with 500 L of 10 mmol/L Tris-HCl, pH 8.0/0.2 mmol/L CaCl 2 buffer alone, with PC/C vesicles, or with AI/PC/C vesicles overnight at 37°C. Aliquots of the control, mutant, or wild-type media, incubated with or without vesicles, were filtered (600 L) through 0.45-m Ultrafree-MC filters (Millipore Corp). Aliquots (500 L) were then separated by Superose 6HR (exclusion limit 4ϫ10 7 M r ) gel-filtration chromatography (1ϫ30-cm column) at a flow rate of 0.8 mL/min of 10 mmol/L Tris-HCl, pH 8.0, with the eluant monitored at 280 nm (ie, for turbidity and aromatic amino acids). Forty 0.8-mL fractions were collected and analyzed individually or after selective pooling. The experiment was repeated except that total incubation volumes were increased to 600 L (300 L of cell medium and 300 L of buffer or vesicles), and the column was equilibrated and eluted with 10 mmol/L Tris-HCl, pH 8.0, containing 0.2 mmol/L CaCl 2 .
Additional PC/C, AI/PC/C, AII/PC/C, and E/PC/C vesicles were prepared as described above. Concentrated (10-fold) control, A20A21, mutant, or wild-type PON1 media (400 L) were each incubated with AI/PC/C vesicles (400 L) in 25 mmol/L Tris-HCl, pH 8.0, containing 1.5 mmol/L CaCl 2 overnight at 37°C. Additional incubations of 400 L of wild-type PON1 media (not concentrated) plus 400 L of AI/PC/C, AII/PC/C, E/PC/C, or PC/C vesicles in 25 mmol/L Tris-HCl, pH 8.0, containing a final concentration of 1.5 mmol/L CaCl 2 were also performed overnight at 37°C. Aliquots were filtered through 0.45-m Ultrafree-MC filters and separated by gel-filtration chromatography, and the fractions were collected as described above, except that the column was equilibrated with 50 mmol/L Tris-HCl, pH 8.0, containing 1 mmol/L CaCl 2 .
Polyacrylamide Gel Electrophoresis (PAGE)/Immunostaining
PAGE was performed in the presence of SDS and ␤-mercaptoethanol except where noted for nondenaturing electrophoresis. Gradient gels (4% to 20% polyacrylamide) were purchased from Novex. Transfer to polyvinylidene difluoride membranes (Bio-Rad) was performed as described elsewhere. 32 
Density Centrifugation
For density centrifugation, concentrated mutant or wild-type medium (75 L) was adjusted to 1.21 g/mL with KBr in 50 mmol/L Tris-HCl, pH 8.0, with 1 mmol/L CaCl 2 . Samples were centrifuged at 100 000g for 24 hours in a fixed-angle rotor in a TL100 ultracentrifuge (Beckman Instruments). To remove KBr from the upper 0.5-mL (dϽ1.21 g/mL) and the lower 2.0-mL infranatant (dϾ1.21 g/mL) fractions, the samples were exchanged into 50 mmol/L Tris-HCl, pH 8.0, with 1 mmol/L CaCl 2 by using Centricon 30 filters (Amicon). The dϽ1.21 g/mL and dϾ1.21 g/mL fractions were assayed for arylesterase activity, separated by SDS-PAGE, and assessed for PON1 immunoreactivity by Western blotting.
Pooled sera (60 L) from 6 C57BL/6J wild-type or 6 apoA-Ideficient mice (3 females and 3 males in each pool) 37 Incubation of Purified, Detergent-Free, Human Serum PON1 and Purified, Delipidated, Human Serum ApoA-I Detergent was removed from purified human serum PON1 by using an Extracti-Gel D column and following the manufacturer's recommendations (Pierce Chemical Co). PON1 (18 g) and apoA-I (345 g) were then incubated either individually or in combination with a 30-fold molar excess of PON1 in 50 mmol/L Tris-HCl, 1 mmol/L CaCl 2 , pH 8.0, at 37°C for 16 hours in a volume of 700 L containing 0.35 mL of the PC/C vesicles described above. After incubation, the mixture was adjusted to a density of 1.21 g/mL with KBr and a final volume of 3.5 mL in 50 mmol/L Tris-HCl, 1 mmol/L CaCl 2 , pH 8.0. Binding of PON1 to phospholipid was determined after ultracentrifugation. The top 0.5-mL, middle 1.5-mL, and bottom 1.5-mL fractions of PON1 were then assayed for arylesterase activity for PON1 localization.
To determine whether PON1 and apoA-I could associate in the absence of phospholipids, the 2 proteins were incubated individually and together with a 30-fold molar excess of PON1 in 50 mmol/L Tris-HCl, 1 mmol/L CaCl 2 , pH 8.0, at 37°C for 16 hours in a volume of 3.5 mL. From this, 30-L aliquots were taken for analysis. The presence or absence of binding between PON1 and apoA-I was determined by assessment of altered electrophoretic migration after nondenaturing PAGE and immunoblotting with anti-apoA-I antiserum alone or in combination with anti-PON1 antiserum.
LDL Oxidation
Human serum LDL was obtained from PerImmune, Inc. Before LDL oxidation, the lipoprotein was dialyzed against EDTA-free PBS, pH 7.4, under N 2 at 4°C. LDL oxidation and peroxidation were analyzed as described previously. 6 In brief, the lipoproteins (100 g of protein per mL) were incubated with 10 mol/L CuSO 4 in air in the absence or presence of the indicated concentrations of recombinant PON1 enzymes for up to 4 hours at 37°C. LDL oxidation was measured directly in the medium by the thiobarbituric acid-reactive substances (TBARS) assay at 532 nm with the use of malondialdehyde to generate a standard curve. Lipoprotein oxidation was also determined by the lipid peroxides test, which analyzes their capacity to convert iodide to I 2 , as measured photometrically at 365 nm. Figure 2 shows that the recombinant A20A21 mutant enzyme is truncated compared with the wild-type recombinant enzyme and that cleavage occurs intracellularly. The estimated sizes of the wild-type and mutant recombinant proteins were 44.2 and 41.6 kDa, respectively. The calculated size difference of Ϸ2.6 kDa is consistent with that expected if the enzyme were cleaved as predicted at the 22nd or 23rd residue. 30 In addition, by using phenyl acetate as the substrate (ie, arylesterase activity), the N-terminal mutant enzyme shows an Ϸ4-fold increase in apparent K m ( Table 1) . The mutant enzyme preparation also had a substantial decrease in activity, showing an Ϸ17-fold lower apparent V max than the wild-type preparation.
The PON1 N-Terminal Hydrophobic Signal Sequence Is Required for Binding to Phospholipids, Proteoliposomes, and Serum Lipoproteins
Bovine lipoproteins present in the expression medium were used to model PON1's association with HDL with and without its N-terminal peptide. Samples of concentrated, recombinant, wild-type and A20A21-mutant PON1 expression media were subjected to density ultracentrifugation at dϭ1.21 g/mL to determine whether the expressed enzymes would colocalize with lipoproteins in the top (ie, dϽ1.21 g/mL) or bottom (ie, dϾ1.21 g/mL) free protein fraction. Figure 3 demonstrates that the wild-type PON1 was present with lipoproteins in the top fractions at dϽ1.21 g/mL. It is also apparent that the wild type was present in the bottom fraction. This could be due to incomplete removal of the top fraction before the remaining sample was concentrated for analysis, or it could be that human recombinant PON1 is displaced from bovine lipoproteins under high salt conditions during ultracentrifugation. Displacement of apolipoproteins during ultracentrifugation is known to occur. 39, 40 The presence of bovine apoA-I in all fractions shows that apoA-Icontaining lipoproteins were present in FBS and were detected by cross-reacting antibodies contaminating the PON1 chicken polyclonal antiserum. This cross-reactivity was observed in concentrated samples only, and the identity of the 28-kDa band as bovine apoA-I in the medium was also confirmed in other experiments with specific antiserum to apoA-I (data not shown). It is notable that apoA-I was found predominantly in the dϽ1.21 g/mL (top) fraction in both the wild-type and mutant PON1 preparations. Mutant PON1, on the other hand, was present exclusively in the dϾ1.21 g/mL fraction, as expected for free proteins. Thus, it appears that the N-terminus was required for association with lipoproteins. However, the inability of mutant PON1 to associate with bovine lipoproteins could have been due to an inability to bind apoA-I, a reduced affinity for bovine apoA-I, an inability to bind to phospholipids, or denaturation of the mutant enzyme.
To better understand the specific requirements for PON1 binding to lipoproteins or their associated phospholipids, we utilized synthetic vesicles and proteoliposomes with defined constituents. We incubated wild-type and N-terminal-deleted PON1 expression media with AI/PC/C and PC/C vesicles overnight at 37°C and followed the elution profile of PON1 and apoA-I by gel-filtration chromatography on Superose 6HR. The large size of the vesicles allowed fractionation by size-exclusion chromatography to assess binding of PON1 enzyme to the vesicles. The large exclusion limit of the column resin also allowed us to distinguish between binding to the vesicles versus extraction of phospholipids by PON1. The presence of vesicles containing the expected apoA-I proteins and lipid was indicated by immunoblotting for apoA-I and through spectrophotometric absorbance at 280 nm, which detected protein and light scattering by the vesicles (Figure 4 ). Adjacent fractions were collected for selective pooling (ie, pools A through D) and assayed for the The hydrophobic signal sequence is required for binding to bovine lipoproteins in expression medium. Expression medium containing wild-type and A20A21-mutant PON1 enzymes were concentrated 10-fold and subjected to centrifugation at dϭ1.21 g/mL. Proteins in the top fractions containing lipids and lipid-associated proteins and bottom fractions containing free protein were separated by SDS-PAGE and immunostained with a chicken antiserum to PON1 and detection with alkaline phosphatase-conjugated rabbit anti-chicken IgG. Under these conditions, bovine apoA-I was also detected by crossreactivity to contaminating anti-human apoA-I immunoglobulins present in the polyclonal chicken anti-human PON1 serum. The presence of apoA-I in the culture medium was also identified in other experiments with specific anti-apoA-I serum.
presence of PON1 and apoA-I by Western blotting with antisera against human PON1 and human apoA-I (Figure 4 , insets). Wild-type PON1 eluted early with the large, AI/PC/C vesicles in pools A and B, with lesser amounts trailing into pool C. In contrast, the N-terminal-deleted enzyme did not associate with the vesicles and eluted predominantly in pool C. ApoA-I-deficient PC/C vesicles were also present predominantly in pools A and B. When incubated with PC/C vesicles, the wild-type enzyme bound to them and eluted in pools A, B, and C. As with the AI/PC/C vesicles, the mutant protein did not associate with the PC/C vesicles and was mostly present in pool C. Endogenous HDL is retained by the column and elutes in pools B and C. It is apparent that when the expression medium is subjected to size-exclusion chromatography without the addition of synthetic vesicles, both the mutant and wild-type proteins are present in pools B and C. However, wild-type PON1 distributes in both pools B and C, whereas the mutant PON1 predominates in pool C, with proteins unassociated with lipoproteins.
Compared with no-vesicle incubations (ie, medium alone), the majority of wild-type PON1 protein shifts to follow the same fractionation pattern as the AI/PC/C vesicles, whereas the N-terminal-mutant fractionation pattern shows no pronounced shift of PON1 to the AI/PC/C vesicles. The shifting of the wild-type enzyme to larger size fractions relative to the medium alone on incubation with AI/PC/C and PC/C vesicles suggested either that the wild type could bind to both apoA-I and phospholipid or that the binding in each case was due to association with phospholipid. The reduced mutant enzymatic activity in unconcentrated preparations made it impossible to reliably follow the A20A21 activity across the fractions to determine whether the lack of binding was due to the loss of the N-terminus or simply to denaturation. To address this problem, wild-type and mutant PON1 expression media were concentrated to allow the loading of more activity on the column after incubation with AI/PC/C vesicles in the presence of increased CaCl 2 (to enhance stability of the mutant enzyme). Analysis of gel-filtration fractions for activity and of PON1 immunoreactivity ( Figure 5 ) demonstrated that both the mutant and wild-type proteins were correlated with their respective activity profiles. Thus, although the mutant protein was active, it could bind to neither PC/C nor AI/PC/C vesicles. These findings strongly suggested that binding of the wild-type enzyme to lipoproteins, AI/PC/C vesicles, and PC/C vesicles was mediated through the retained N-terminal hydrophobic signal sequence. The observation that the presence or absence of apoA-I had no impact on A20A21 PON1 binding to vesicles also indicated that there were not two distinct sites on PON1 for binding of phospholipid and apoA-I, respectively. Furthermore, the exclusion limit of the column used was far larger than that anticipated if PON1 were simply extracting phospholipid from the vesicles. Clearly, PON1 was associating directly with the vesicles. This result suggested that PON1 had transferred between the phospholipid surfaces of the lipoproteins and vesicles. It seemed that the vesicle binding was due to direct phospholipid binding to the N-terminal peptide; however, the presence of bovine lipoproteins in all expression media could have facilitated the transfer of PON1 to the vesicles through the cotransfer of apoA-I.
Wild-Type PON1 Does Not Require ApoA-I to Bind to Phospholipid
To clarify the nature of PON1 binding to the synthetic vesicles, we tested whether purified PON1 from human sera could bind directly to PC/C vesicles in the presence and absence of apoA-I. The methods used to purify human PON1 remove virtually all contaminating apoA-I. Thus, if apoA-I were required for PON1 to associate with phospholipid, only a very low percentage of purified PON1 would be able to bind as a result of apoA-I contamination. We incubated purified PON1 with PC/C vesicles in the presence and absence of a 30-fold molar excess of apoA-I and separated the vesicles by density ultracentrifugation at dϭ1.21 g/mL. Figure 6A shows that PON1 activity predominantly bound to vesicles in the dϽ1.21 g/mL fraction. The addition of apoA-I to the vesicles did not increase vesicle PON1 binding. Thus, we concluded that PON1 is capable of binding to phospholipids directly, without the addition of apolipoproteins.
Wild-Type PON1 Does Not Bind Directly to ApoA-I in the Absence of Phospholipid
The above results do not preclude the possibility of a direct association between PON1 and apoA-I under some circumstances. Therefore, we determined whether PON1 could bind directly to apoA-I in the absence of lipid. Purified, delipidated apoA-I and detergent-free PON1 were incubated under identical conditions as presented in Figure 6A but without the PC/C vesicles. Nondenaturing PAGE and immunoblotting were performed to assess whether PON1 and apoA-I had associated, as indicated by a change in the migration of these proteins in combination, compared with the proteins alone. No alteration in the migration patterns of the 2 proteins was observed when incubated together ( Figure 6B ). Therefore, we were unable to obtain any evidence for a direct association between the 2 proteins.
Phospholipid Competes With Nonionic Detergent for Binding to the N-Terminus to Stimulate PON1 Activity
The addition of nonionic detergents directly to serum or during PON1 purification decreases PON1 arylesterase and paraoxonase activities by Ϸ50%. 22, 23, 41 Phospholipid addition restores these activities. 22 We speculated that detergent induced the loss of activity resulting from phospholipid removal from PON1's N-terminus. To test this hypothesis, A20A21 mutant and wild-type PON1s were treated with Triton X-100 alone, Triton X-100 in combination with PC/C vesicles, and with PC/C vesicles alone. Mutant PON1 was unaffected by all 3 treatments (Figure 7) . In contrast, the wild type lost nearly half of its activity after treatment with detergent, whereas treatment with detergent plus PC/C vesicles protected this activity. Wild-type PON1 activity was also stimulated by PC/C vesicles alone (17% increase). The degree of stimulation was less than that reported by Kuo and La Du, 22 but this was expected, because the wild-type enzyme was already partially stimulated by the phospholipids present in FBS. These results suggest that PON1's N-terminal binding to phospholipid stimulates the enzyme's activity.
ApoA-I Stabilizes PON1 Activity In Vitro
We observed that the presence of phospholipid enhanced wild-type PON1 activity during size-exclusion chromatography compared with medium alone (Figure 8 ). We also observed that apoA-I further augmented this effect (Figure 8 ). To determine whether this effect was unique to apoA-I or a generalized feature of apolipoproteins, wild-type recombinant PON1 was incubated with AI/PC/C, AII/PC/C, E/PC/C, or Figure 6 . Purified serum PON1 binds to phospholipids directly and does not require apolipoproteins. A, Incubation of purified serum PON1 with PC/C vesicles with (open bars) and without (black bars) apoA-I. PC/C vesicles were incubated with detergent-free, purified, human serum PON1 alone or with a 30-fold excess of delipidated apoA-I in 50 mmol/L Tris-HCl, pH 8.0, and 1 mmol/L CaCl 2 for 16 hours at 37°C in a reaction volume of 3.5 mL. After incubation, the samples were adjusted to dϭ1.21 g/mL with KBr and separated by ultracentrifugation. The top 0.5-mL (containing vesicles and vesicle-associated protein), middle 1.5-mL, and bottom 1.5-mL (containing free proteins) fractions were carefully aspirated and assayed for arylesterase activity. Activity is indicated on the left as a percentage of the total activity present in all fractions combined. B, Incubation of PON1 and apoA-I individually and in combination in the absence of phospholipids. Detergent-free, purified, human serum PON1 and delipidated apoA-I were incubated individually or in combination in 50 mmol/L Tris-HCl, pH 8.0, and 1 mmol/L CaCl 2 for 16 hours at 37°C in a reaction volume of 3.5 mL. ApoA-I was present in a 30-fold molar excess whether incubated alone or with PON1. Association between apoA-I and PON1, and any resulting alteration in migration of PON1, was assessed by fractionating the samples through nondenaturing 4% to 20% polyacrylamide gradient gels. Samples were run in duplicate, followed by electroblotting to polyvinylidene difluoride membranes. Lanes 1 through 3 were then immunostained for both PON1 and apoA-I with a 1:1000 dilution of chicken antihuman PON1 and sheep anti-human apoA-I sera, respectively. Lanes 4 through 6 were immunostained for apoA-I alone with a 1:6000 dilution of sheep anti-human apoA-I. In all cases, chicken IgG was detected with alkaline phosphatase-conjugated rabbit anti-serum, and sheep IgG was detected with alkaline phosphatase-conjugated donkey anti-serum. Lanes 1 and 4 represent apoA-I alone. Lanes 2 and 5 represent PON1 alone. Lanes 3 and 6 represent PON1 and apoA-I when incubated together.
PC/C control vesicles. After size-exclusion chromatography, PON1 activity was determined in pooled fractions ( Figure 9 ). Minor differences in the shapes of the activity profiles for the individual vesicle preparations is likely, secondary to variations in the size distribution within each vesicle type. However, when the total activity between treatments was compared through summation of activities across all fractions, it was observed that the PC/C, AII/PC/C, and E/PC/C vesicles had only 77%, 74%, and 82% of AI/PC/C's activity, respectively. These data were obtained at increased CaCl 2 concentration compared with that shown in Figure 8 , in which activities were 54% and 13% of the apoA-I-treated enzyme in the presence of PC/C vesicles and medium alone. Thus, the stabilizing effects of phospholipid, apoA-I, and CaCl 2 appear to be additive. Nonetheless, the presence of apoA-I in vesicle preparations consistently resulted in higher activity than that seen with other treatments.
PON1 Is Expressed at Reduced Levels in HDL in the Absence of ApoA-I, and It Is Less Stable
Although apoA-I did not appear to be essential for binding of PON1 to phospholipid, the close in vivo association between the two proteins combined with the in vitro evidence for PON1's stabilization by apoA-I suggested that apoA-I may play a similar role in the in vivo expression of PON1. To determine whether apoA-I was required for PON1 expression in vivo, we measured the arylesterase activity in apoA-Ideficient mice. 37 Sera obtained from age-matched, male and female, control and apoA-I-deficient C57BL/6 mice were assayed for arylesterase activity. Sex-dependent dimorphism in arylesterase activity was observed in both control and apoA-I-knockout mice, with females always expressing higher levels than males (Table 2) . In control animals, the degree of difference between the sexes diminished as the mice aged, mainly due to a decrease of enzyme activity in the females. In apoA-I-deficient mice, arylesterase levels, on the other hand, remained stable. Age-related fluctuations in mouse serum PON1 was also noted by Li et al, 28 who observed a 3-fold variation in serum organophosphatase activities between 1-day-old animals and adults, with a peak activity occurring at 20 days. The mice used in our study were obtained when they were 60 days old, and future studies will need to focus on whether the decrease in arylesterase activity in control females is age related or due to environmental changes.
To determine whether reduced arylesterase levels in the apoA-I-knockout mice resulted from an inability of PON to bind to apoA-I-deficient HDL, sera from control and apoA-I-deficient animals were pooled and subjected to isopyknic density ultracentrifugation, and an analysis of arylesterase activity and PON1 distribution in the density fractions was performed. Figure 10A shows arylesterase activity in the isopyknic density gradient fractions of pooled sera from the apoA-I-deficient (3 females and 3 males) and control (3 females and 3 males) mice. Total arylesterase activity was reduced and was present in a single, very high density peak (dϭ1.18 to 1.22 g/mL) in the apoA-I-deficient mice. In control mice, 2 peaks of arylesterase activity were observed, one at dϭ1.07 to 1.15 g/mL and the other at dϭ1.18 to 1.22 g/mL. This distribution is consistent with observations in humans, in whom PON1 associates with both HDL 2 and HDL 3 subtypes. 42 The apoA-I-deficient serum, which lacked the larger peak but retained the smaller, denser peak, suggests that most PON1 can still associate with HDL, independent of apoA-I. Mice lacking apoA-I show an increase in expression of apoA-II and apoE. 43, 44 It is likely that the smaller peak of activity associated with the VHDL fractions in the apoA-Ideficient mouse represents an HDL species containing 1 or more of these apolipoproteins. These data suggest that PON1 is secreted less efficiently or is less stable in the absence of apoA-I.
PON1's presence in apoA-I-deficient HDL and its ability to bind to phospholipid directly suggests that PON1 binds to HDL through phospholipids, like those present in cell membranes, and could be competitively removed from HDL by phospholipids. To test this hypothesis, we incubated pooled sera from control mice and from apoA-I-deficient mice with PC/C vesicles, followed by fractionation through isopyknic ultracentrifugation. As shown in Figure 10B , virtually all arylesterase activity in both control and apoA-I-knockout mice was transferred to the dϽ1.06 g/mL fraction containing the vesicles (ie, top fraction). Again, we questioned whether this was due to a transfer of PON1 and apolipoproteins in tandem. The apoA-I antiserum used for these studies had no immunoreactivity in the deficient animals, as verified by Western blotting of delipidated serum ( Figure 10C) . If the transfer of PON1 to lipid were mediated through apolipoproteins, it would likely be a generalized feature and not unique to apoA-I. To directly assess whether apoA-I cotransferred with PON1 to phospholipid vesicles, desalted and delipidated aliquots from fractionated control serum incubated without PC/C vesicles ( Figure 10A , solid circles) and with PC/C vesicles ( Figure 10B , solid circles) were immunostained for apoA-I ( Figure 10D ). Figure 10D (bottom panel) shows that fractions 1 and 2, which contained virtually all PON1 activity added ( Figure 10B , solid circles), lacked apoA-I. These data demonstrate that PON1 transferred independently to the *Arylesterase activity is defined as g phenyl acetate hydrolyzed per minute per mL serum. Assays were performed at 25°C with 1 mmol/L phenyl acetate as the substrate in 50 mmol/L Tris-Cl, pH 8.0, 1 mmol/L CaCl 2 . Values represent means of measurements from 3 animals ϮSE. Figure 10 . PON1 associates with HDL in vivo in the absence of apoA-I and can be competitively removed from HDL by phospholipid. Black circles indicate control serum; white squares, apoA-I-deficient serum. A, Sixty microliters of pooled mouse sera (3 male, 3 female) from either wild-type or apoA-I-deficient mice were added to 60 L of 50 mmol/L Tris-HCl, pH 8.0, with 1 mmol/L CaCl 2 and incubated for 16 hours at 37°C. Isopyknic density centrifugation was performed with a KBr gradient of dϭ1.05 to 1.25 g/dL. Individual fractions were carefully aspirated and assayed for arylesterase activity. Activity is given on the vertical axis as units g phenyl acetate hydrolyzed/min per mL of each fraction. B, Isopyknic density gradient ultracentrifugation of an equal volume of pooled mouse sera was performed as in A, except that mouse sera were incubated with PC/C vesicles present in 50 mmol/L Tris-HCl, pH 8.0, with 1 mmol/L CaCl 2 . Activity was assayed as in A and is represented in units/mL on the vertical axis for each fraction. C, ApoA-I-deficient mice do not express immunodetectable serum apoA-I. Aliquots of pooled sera from wild-type and apoA-I-deficient animals were delipidated, fractionated by SDS-PAGE, and Western blotted with a rabbit anti-rat apoA-I that cross-reacts with mouse apoA-I. D, PON1 is competitively removed from HDL by phospholipids without cotransfer of apoA-I. The samples from wild-type sera in A and B were desalted, delipidated, fractionated by size by SDS-PAGE, electroblotted to polyvinylidene difluoride membranes, and immunostained as in C.
phospholipid vesicles. The observed shifting of apoA-I to less-dense HDL fractions on incubation with PC/C vesicles is likely due to phospholipid enrichment of endogenous HDL by serum enzymes, such as phospholipid transfer protein.
Thus, we demonstrated that PON1's association with HDL was mediated through phospholipid binding to the retained N-terminal hydrophobic peptide and that PON1 can transfer from HDL to other phospholipid surfaces through this retained peptide.
We observed that arylesterase activity in apoA-I-deficient sera decreased more rapidly than that in sera from control animals after storage at 4°C. This finding suggested that PON1 may be less stable in apoA-I-deficient HDL. To directly test this observation, diluted, pooled sera from control and apoA-I-deficient animals were incubated separately at 37°C overnight. Control serum retained nearly 90% of its original activity while the activity of the knockout mice serum had fallen to Ϸ65% of pretreatment values ( Figure 11 ). These data suggest that PON1 is less stable in the absence of apoA-I and provide further evidence that apoA-I enhances PON1's activity and stability in vivo through a preferred presentation on HDL phospholipid.
The PON1 N-Terminal Hydrophobic Signal Sequence Is Not Essential for Protection Against LDL Oxidation
A recent report has suggested that phospholipids themselves may protect LDL from oxidation. 45 We questioned whether the observed protection of LDL by PON1 was due to the phospholipids bound to the N-terminus of PON1. Figure 12 presents data from the copper ion-induced oxidation of purified LDL in the presence of control expression medium, PON1 (type Q) recombinant medium, and medium containing the recombinant N-terminal mutant. It is evident that equal amounts of mutant and wild-type activity result in equal protection against LDL oxidation, as measured by peroxide production and TBARS formation. In this assay, wild-type and N-terminal-deleted PON1 enzymes were added by activity rather than mass. This required that the medium for the wild-type PON1 be diluted to 0.02 arylesterase units per mL with an appropriate-mutant PON1 reduced copper ioninduced LDL oxidation by Ϸ35% in both the peroxides and TBARS assays (Figure 12) . Nonetheless, the decreased V max and increased K m of the N-terminal mutant (Table 1) with phenyl acetate as the substrate suggested that its affinity for other lipophilic substrates and rate of hydrolysis might also be reduced. This concept is consistent with the fact that more mutant protein was present in the LDL oxidation assays for the preparation to have equal activity. To determine whether this activity represented the same amount of an equally protective mutant protein (diluted by additional inactive, unstable mutant protein) compared with wild-type protein or more of an active mutant protein with reduced affinity will require the development of techniques to separate or distinguish active PON1 protein from inactive enzyme in the same preparation. Even so, the fact that the N-terminal mutant inhibited the oxidative damage of LDL despite its inability to bind phospholipids demonstrates that PON1's protective actions are not simply through presentation of phospholipids and provides further evidence for a catalytic mechanism.
Discussion
PON1 is distinctive in that it interacts with serum lipoproteins. This association, in combination with studies showing that PON1 can protect LDL from oxidative damage in artificial systems, suggests that PON1 has a protective role in vivo and inhibits the development of vascular and coronary diseases. A positive correlation between apoA-I and PON1 levels in vivo, combined with its absent or low activities observed in apoA-I deficiencies such as Tangier disease and fish-eye disease, 46, 47 suggested that apoA-I was required for the expression of PON1 as well as its binding to HDL. Nonetheless, before this current investigation, no data were available about the role of apoA-I in PON1 expression, the means of PON1's association with HDL, or the structural requirements for this association.
We have now demonstrated that PON1's association with HDL requires the retention of its hydrophobic N-terminal signal peptide. Through site-directed mutagenesis, a cleavable signal peptide was created. Using egg PC/C vesicles and separation techniques based on density or size, we have demonstrated that PON1 associates with lipoproteins and lipid-containing particles by binding phospholipids directly to its hydrophobic signal peptide. Furthermore, the significance of the coexistence of PON1 and apoA-I in HDL and the apparent protein-protein interaction between the two proteins were also investigated by a variety of methods, including characterization of PON1 activity and distribution in the sera of apoA-I-deficient mice and physical studies of purified human PON1 and human apoA-I. In both wild-type and apoA-I-deficient mouse sera, PON1 activity was associated with HDL. When PC/C vesicles were incubated with either wild-type or apoA-I-deficient mouse serum, essentially all PON1 activity shifted to the vesicles independently of apoA-I, suggesting that PON1 binding to HDL is primarily due to the binding of PON1's N-terminus to phospholipid, rather than to apoA-I. Consistent with these findings was our inability to induce a physical association between PON1 and apoA-I in a lipid-free, in vitro system. Hence, it appears that lipid is required for the association of apoA-I and PON1. Although apoA-I was not required for PON1 expression, phospholipid binding, or HDL association, the presence of apoA-I conferred increased PON1 heat stability in mouse serum and consistently resulted in higher arylesterase activity in in vitro studies, a feature not seen with other apolipoproteins tested. These data suggest that apoA-I provides an optimal presentation of phospholipid for PON1 binding, stabilization, and stimulation. Hence, distinct HDL subtypes containing apoA-I may compete for PON1 by presenting a preferred configuration of phospholipids for binding to the hydrophobic N-terminus rather than by binding to apolipoproteins. Serum PON1 levels are altered by diet, 29 acutephase reactants (as is apoA-I), 48 pregnancy, 49 and disorders affecting apoA-I metabolism. 46, 47 These findings, our observations of fluctuations in arylesterase activities unique to female mice expressing apoA-I, and the observed stabilizing actions of apoA-I on PONI activity suggest that hormonal and other circulating factors may alter PON1's biological activities, in part through their effects on the expression and metabolism of apoA-I.
Recombinant and serum-purified paraoxonase preparations likely contain both catalytically active and inactive PON1 protein. At present, we are unable to distinguish active from inactive PON1 protein in these preparations. Consequently, it is not possible to rigorously explain the observed lower apparent V max (activity per mg protein) of the N-terminalmutant preparations. This preparation may contain significant amounts of inactive but still immunoreactive protein that confounds our efforts to quantify the amount of active enzyme present. When purified PON1, recombinant PON1, or mouse serum was added to phospholipid vesicles, activity was protected under several experimental conditions. This finding provides strong evidence that PON1 is stabilized or stimulated in the presence of phospholipid. Presumably, the decrease in apparent V max of the mutant enzyme is due to its inability to bind phospholipid. Thus, the mutant enzyme may be unable to access substrates efficiently, which normally partition into phospholipids. The observed increase in K m for phenyl acetate hydrolysis by the mutant enzyme indicates that interaction of the wild-type enzyme with its substrates involves the retained hydrophobic N-terminus. All known substrates of PON1 are hydrophobic and partition into a lipid phase, and therefore the protein's association with HDL or phospholipid may be important for its enzymatic function. The lipophilicity of the N-terminus or of its bound lipid may facilitate the binding of substrate and increase the concentration in the immediate environment of the enzyme. Similarly, these qualities may influence the transfer of substrate to the active site or its release.
Surprisingly, both mutant and native recombinant PON1s were effective in blocking copper ion-induced oxidation of LDL. These results were obtained on the basis of the addition of equal units of activity in the assay, which therefore required more mutant protein to be present to achieve activity levels equal to that of the wild-type PON1. As discussed above, it is not possible to determine how much of the mutant protein was active. The two recombinant enzymes appear to be equally effective in protecting LDL against oxidation, thus suggesting that the kinetic parameters for phenyl acetate hydrolysis are not representative of those for the products of LDL oxidation. In contrast, it may be argued that more mutant protein was required for equal protection to overcome the reduced affinity for substrates, as predicted by the increased K m for phenyl acetate. Nonetheless, it is clear that phospholipid binding through the N-terminus is not essential for protection of LDL from oxidation. It has recently been shown that the active site and cofactor requirements for LDL protection by PON1 differ from those for arylesterase activity, 6 and it is possible that PON1 activity with the products of LDL oxidation is not significantly altered by loss of the N-terminus. Alternatively, PON1 may also act stoichiometrically, perhaps through reactions involving its free sulfhydryl group (C283). This site may allow PON1 to act as a "biological buffer" to absorb damage induced during oxidation. It may also be in or near the catalytic site that provides enzymatic protection of LDL from oxidation. 6 It is important to note that there is no evidence for the direct binding of PON1 to LDL. PON1's function in reducing LDL oxidation may require lipid exchange or absorption of oxidative damage products rather than direct binding of PON1 to LDL.
There is little evidence for the presence of PON1's circulating in plasma as a free protein in vivo. The current study demonstrates that PON1 binds phospholipids with high affinity. The finding that phospholipids competitively remove PON1 from HDL suggests that PON1 may exchange with other phospholipid depots, such as cellular membranes. Although we did not directly measure nor explore this further in the current study, on the basis of our findings, we postulate that PON1 may migrate between HDL and cell membranes. Apolipoproteins show preferential binding for specific phospholipid types, 50 as do other HDL proteins such as lecithincholesterol acyltransferase. 51 PON1 not only binds to phospholipids but is also stimulated by them; however, phospholipid subtypes vary in their degree of stimulation. 22 Because of an optimal presentation of commonly preferred phospholipids, apoA-I may serve as a shuttle for PON1 distribution from the liver to distal sites of lipid damage. Therefore, the association of PON1 with HDL may be required for the appropriate physiological distribution of the enzyme for it to have a significant biological impact.
The retention of an N-terminal hydrophobic signal peptide in a secreted protein is an extremely unusual feature. We are aware of only 1 other such protein with this rare characteristic, the human haptoglobin-related protein. Interestingly, the haptoglobin-related protein associates with PON1 and apoA-I in an anti-trypanosomal HDL subset that exhibits peroxidase activity and is referred to as trypanosomal lytic factor. 52 Trypanosomal lytic factor protects humans from infection with Trypanosoma brucei, possibly through oxidative damage resulting from its peroxidase activity. Furthermore, HDL is also known to bind 53 and to provide in vivo protection against endotoxin. 54, 55 These observations, combined with the strong evidence for PON1's antiatherogenic activities and its localization to sites of oxidative damage, including the interstitium, vascular smooth muscle, and atherosclerotic plaques, 2, 56, 57 suggest that retention of the N-terminal hydrophobic leader sequence may have evolved to facilitate the delivery and transfer of lipid-binding proteins to inactivate toxic lipid products resulting from oxidative damage, infection, and inflammation. Such a model is presented in Figure  13 . We suggest that PON1 leaves the hepatocyte plasma membrane by binding to apoA-I-associated phospholipids under nonequilibrium conditions to circulate with HDL. Under conditions more closely approximating a steady state, the ability of phospholipids to competitively remove PON1 from HDL would allow the enzyme to diffuse from the relatively small, phospholipid-binding area of HDL to the extensive phospholipid depots present at sites of lipid damage and LDL accumulation, such as endothelial cells, the interstitium, and smooth muscle cell membranes. Figure 13 . Potential role for the retained hydrophobic N-terminal peptide in PON1's association with HDL and its transfer to sites of oxidative and inflammatory injury. 1, PON1 transits the default secretory pathway and is bound to the hepatocyte plasma membrane, as expected for a protein with a retained hydrophobic N-terminal signal peptide. PON1's N-terminus associates with HDL phospholipids and is stabilized by apoA-I. Movement of HDL particles away from hepatocytes prevents diffusion back to the hepatocyte plasma membrane. 2, PON1 is able to enter the intravascular space with HDL. 3, PON1 transfers to phospholipids in plasma membranes through its N-terminus under more static conditions favoring diffusion, perhaps during apoA-I-mediated recruitment of cholesterol from endothelial or smooth muscle cells. 4, PON1 may therefore have access to the interstitium and areas of LDL accumulation and oxidative damage. The retained hydrophobic N-terminal signal peptide is represented by a thick, black line. EC indicates endothelial cells; SMC, smooth muscle cells; MØ, macrophages; ECM, extracellular matrix; Ox-LDL, products of LDL oxidation; and CE, cholesteryl esters.
